Abstract: Certain aspects of the disclosure provide a method for fine-tuning a language model (LM) including obtaining a first conversation stream of a first conversation, wherein the first conversation stream includes one or more messages and one or more events; mapping an event to at least one message of the one or more messages, the mapping being performed using at least one of event-based labeling or content-based labeling; and fine tuning a language model (LM) using the event and the at least one message that are mapped, the fined-tuned LM being configured for: determining one or more tools that are external to the fine-tuned LM and invokable, by the fine-tuned LM, at least to generate an output that is related to the event and the at least one message, the output being usable by the fine-tuned LM during a second conversation to perform one or more actions.

Abstract: Systems and methods are provided for adding a detection mechanism and validation means to identify faulty devices to effectively manage them to improve network accessibility metrics. Carrier configuration can be utilized to dynamically disable/enable certain layers/bands/RAT in order to effectively manage which devices can attach to the network and to which layers they may attach. Such management techniques can be utilized when devices have met a predetermined failure threshold indicating the device has failed to return a radio resource control (RRCE) connection setup complete message a predetermined number of times within a predetermined time period (e.g., 10 failures within an hour from the same cell). This likely indicates a bad actor attempting to access the network and should be handled appropriately.

Abstract: Systems and methods are provided for dynamically assigning carrier aggregation to user equipment (UE) utilizing backhaul limits as an initial threshold. Backhaul limits are bottlenecks for data in telecommunications networks. By assigning carrier aggregation based on backhaul limit constraints, networks can optimize carrier aggregation activation and optimize resource allocation within the network. Networks stand to benefit from discontinuing blind activation of carrier aggregation when the addition of more cells assigned to the UE do not impact the maximum data throughput achieved in view of the backhaul limits experienced by the network at a given time.

Abstract: Systems, methods and devices are provided for minimizing unnecessary inter-radio access technology (IRAT) transitions. A method includes determining that a wireless device has experienced a threshold number IRAT handovers in a predetermined time period, identifying a trigger for the inter-RAT handovers and assigning the wireless device to a selected RAT based on the identified trigger.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: A system and method of unloading a heart chamber is described. The chamber can be a ventricle and the system can unload the ventricle during or after a heart attack. The ventricular unloading system includes a transthoracic needle insertable into the ventricle, a vascular access cannula insertable into a blood vessel, and a pump to move blood from the ventricle to the blood vessel through the transthoracic needle and the vascular access cannula. The ventricular unloading system can be used by an emergency medical technician in a non-hospital setting. Accordingly, the ventricular unloading system can provide early protection against infarct to improve clinical outcomes for a patient. Other embodiments are also described and claimed.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-05 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: A system and method of unloading a heart chamber is described. The chamber can be a ventricle and the system can unload the ventricle during or after a heart attack. The ventricular unloading system includes a transthoracic needle insertable into the ventricle, a vascular access cannula insertable into a blood vessel, and a pump to move blood from the ventricle to the blood vessel through the transthoracic needle and the vascular access cannula. The ventricular unloading system can be used by an emergency medical technician in a non-hospital setting. Accordingly, the ventricular unloading system can provide early protection against infarct to improve clinical outcomes for a patient. Other embodiments are also described and claimed.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: Incident capture systems and methods for a vehicle. One example system includes a head unit that displays a user interface to view and manage incident images. The system also includes an existing vehicle sensor configured to sense conditions outside of the vehicle, an existing vehicle camera configured to capture conditions outside of the vehicle, and an electronic controller. The electronic controller is configured to detect a change in the conditions outside of the vehicle from the existing sensor; determine a state of the system, wherein the state of the system is one selected from the group consisting of an on state and an off state; and in response to determining an on state, receive at least one image from the existing vehicle camera; and store the at least one image in a stack located in a non-transitory computer-readable storage medium.

Abstract: Incident capture systems and methods for a vehicle. One example system includes a head unit that displays a user interface to view and manage incident images. The system also includes an existing vehicle sensor configured to sense conditions outside of the vehicle, an existing vehicle camera configured to capture conditions outside of the vehicle, and an electronic controller. The electronic controller is configured to detect a change in the conditions outside of the vehicle from the existing sensor; determine a state of the system, wherein the state of the system is one selected from the group consisting of an on state and an off state; and in response to determining an on state, receive at least one image from the existing vehicle camera; and store the at least one image in a stack located in a non-transitory computer-readable storage medium.

Abstract: Embodiments of the disclosure enable contextual user experiences to be provided. A computing system receives sensor data from an appliance associated with a first user account, and analyzes the sensor data to identify a product and one or more second user accounts associated with the product. The second user accounts are used to aggregate product data associated with the product, and the product data is used to generate catalog data associated with the product. The catalog data includes one or more portions associated with the second user accounts and is transmitted to a client device associated with the first user account to prompt a first user to enter into a transaction associated with the product. Each portion of the catalog data is selectable to facilitate the transaction between the first user and a respective second user associated with the second user accounts.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: Embodiments of the disclosure enable contextual user experiences to be provided. A computing system receives sensor data from an appliance associated with a first user account, and analyzes the sensor data to identify a product and one or more second user accounts associated with the product. The second user accounts are used to aggregate product data associated with the product, and the product data is used to generate catalog data associated with the product. The catalog data includes one or more portions associated with the second user accounts and is transmitted to a client device associated with the first user account to prompt a first user to enter into a transaction associated with the product. Each portion of the catalog data is selectable to facilitate the transaction between the first user and a respective second user associated with the second user accounts.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.